Rakeen Mabud on Greedflation / Rachel K. Jones on Mifepristone

KPFA - CounterSpin

This week on CounterSpin:

In the final quarter of 2023, after-tax corporate profits reached an all-time high of $2.8 trillion. As reported by Popular Information, corporate profit margins were at a level not seen since the 1950s, as increases in prices have outpaced increases in costs. Capitalism 101 says this shouldn’t happen, because competing companies will step in with lower prices and grab some market share, right? What’s different now? Abject greed, abetted by policy, and whistled past by the press corps. As one economist put it, “If people are paying $3 for a dozen eggs last week, they’ll pay $3 this week. And firms take advantage of that.” One reason we have details on “greedflation” is the work of the Groundwork Collaborative. We spoke with their economist and managing director of policy and research, Rakeen Mabud, a few months back.

Advocates warned that overturning Roe v. Wade would not be the end, and it wasn’t. The court is now entertaining challenge to the legality of the abortion medication mifepristone, used safely and effectively for decades, including invoking the 1873 Comstock Act, about sending “obscene materials” through the mail. The Washington Post has described it as a “confusing legal battle,” but CounterSpin got clarity from the Guttmacher Institute’s Rachel K. Jones last year.

The post Rakeen Mabud on Greedflation / Rachel K. Jones on Mifepristone appeared first on KPFA.